Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients
Autore:
Barnas, C; Quiner, S; Tauscher, J; Hilger, E; Willeit, M; Kufferle, B; Asenbaum, S; Brucke, T; Rao, ML; Kasper, S;
Indirizzi:
Univ Vienna, Dept Gen Psychiat, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Gen Psychiat, A-1090 Vienna, Austria Univ Vienna, Dept Clin Neurol, Vienna, Austria Univ Vienna Vienna Austria iv Vienna, Dept Clin Neurol, Vienna, Austria Wilhelminenspital Stadt Wien, Dept Neurol, Vienna, Austria Wilhelminenspital Stadt Wien Vienna Austria ept Neurol, Vienna, Austria Univ Bonn, Dept Psychiat, D-5300 Bonn, Germany Univ Bonn Bonn Germany D-5300 Bonn, Dept Psychiat, D-5300 Bonn, Germany
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 157, anno: 2001,
pagine: 236 - 242
Fonte:
ISI
Lingua:
ENG
Soggetto:
EMISSION TOMOGRAPHY SPET; DOUBLE-BLIND TRIAL; NEUROLEPTIC DRUG; IN-VIVO; ATYPICAL NEUROLEPTICS; NEGATIVE SYMPTOMS; ZOTEPINE; CLOZAPINE; HALOPERIDOL; RISPERIDONE;
Keywords:
zotepine; dopamine D2 receptor; 123I IBZM; SPECT; atypical antipsychotic drug;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Barnas, C Univ Vienna, Dept Gen Psychiat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
C. Barnas et al., "In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients", PSYCHOPHAR, 157(3), 2001, pp. 236-242

Abstract

Rationale: Single photon emission computed tomography (SPECT) using I-123 iodobenzamide (IBZM) as tracer substance has been shown to be a useful toolto visualize dopamine 2 (D2) receptor occupancy. Objectives: We investigated the striatal D2 receptor occupancy of zotepine which is referred to the class of atypical antipsychotic drugs. Methods: I-123 IBZM and SPECT were used to visualize striatal dopamine 2 (D2) receptor occupancy in zotepine-treated schizophrenic patients. Two groups of schizophrenic patients receiving either 150 mg/day zotepine (n=6) or 300 mg/day (n=6) underwent examination. For the quantification of striatal D2 receptor occupancy, striatal IBZM binding in patients treated with antipsychotics was compared to untreated healthy controls (n=8) reported earlier. Results: Zotepine led to a mean overall striatal D2 receptor occupancy of 73%. Patients with 150 mg daily showed a significantly lower occupancy (65.8%, SD=6.2) than patients with 300 mg/day (77.8%, SD=10.7; P <0.05). No clinically relevant extrapyramidal sideeffects occurred during treatment with zotepine. Conclusions: There was nocorrelation between the degree of striatal D2 receptor occupancy and clinical improvement.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/09/19 alle ore 23:17:20